@Article{Nazzal2009,
journal="Gastroenterology Review/Przegląd Gastroenterologiczny",
issn="1895-5770",
volume="4",
number="1",
year="2009",
title="Treatment of chronic hepatitis B and drug resistance",
abstract="For more than ten years standard therapy of chronic hepatitis B was limited to interferon-a and lamivudine. Interferon-a is known to have several adverse effects, while the use of lamivudine is associated with HBV (hepatitis B virus) mutations. New nucleoside/nucleotide analogues have been registered during the last few years. New antiviral agents with different mechanisms of action than that of nucleotide/nucleoside analogues should be used in the future to achieve the optimal goal of therapy: the total eradication of HBV infection.",
author="Nazzal, Khalil",
pages="7--11",
url="https://www.termedia.pl/Treatment-of-chronic-hepatitis-B-and-drug-resistance,41,11938,1,1.html"
}